Colonics
About Me
Recent Posts
- 4 Mushroom Poisonings In 2 Weeks - Doctors Test Milk Thistle As Treatment
- Improved Diagnostics For Sleeping Sickness
- Prostate Growth May Be Slowed By Statins
- New Tools For Psychological Science Research - Facebook And Smartphones
- Finding That Oxytocin Improves Brain Function In Children With Autism Could Lead To Treatment For Associated Social Deficits
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | |||
Friends
Links
Entry 1 of 2380
Last Page | Next Page
10/21/2009
-
Lux Biosciences to present on LX211 at 2009 AAO annual conference
|
Lux Biosciences, Inc., a privately held biotechnology company focused on the progress and commercialization of therapies for serious ophthalmic diseases, today announced that the company’s empirical drug LX211 (LUVENIQ; oral voclosporin) will be be included in several More: - Read More |
Post A Comment! :: Send to a Friend! |
Share and enjoy
